BTK drugs for Relapsed/Refractory Chronic Lymphocytic Leukemia
2 tracked BTK drugs in the Relapsed/Refractory Chronic Lymphocytic Leukemia race. The class explanation lives on the BTK page; the full indication pipeline across every mechanism is on the Relapsed/Refractory Chronic Lymphocytic Leukemia page.
2 approved / phase 4
Head-to-head evidence: Acalabrutinib vs Pirtobrutinib